Amyotrophic Lateral Sclerosis (ALS) Market to Register Incremental Growth During the Forecast Period (2022-32), Asserts DelveInsight | Amylyx (RELYVRIO), Cellenkos (CK0803), Biogen, Ionis, MediciNova

September 30 19:14 2022
Amyotrophic Lateral Sclerosis (ALS) Market to Register Incremental Growth During the Forecast Period (2022-32), Asserts DelveInsight | Amylyx (RELYVRIO), Cellenkos (CK0803), Biogen, Ionis, MediciNova
Delveinsight Business Research LLP
Amyotrophic Lateral Sclerosis (ALS) Market size in the seven major markets was USD 401.19 Million in 2020, which is expected to grow in the coming years. The market is expected to increase owing to the rise in the number of diagnosed prevalent cases and the launch of emerging therapies.

There are approx. 100+ key companies which are developing therapies for Amyotrophic Lateral Sclerosis (ALS). Currently, Amylyx Pharmaceuticals has its Amyotrophic Lateral Sclerosis (ALS) drug candidates in the most advanced stage of clinical development.

DelveInsight’s “Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Amyotrophic Lateral Sclerosis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Amyotrophic Lateral Sclerosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Amyotrophic Lateral Sclerosis Market

Amyotrophic Lateral Sclerosis: An Overview

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases mainly involving the nerve cells (neurons) responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by the gradual deterioration and death of motor neurons. 

ALS can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. The terms familial and genetic mean that this type of ALS is inherited. In families with genetic ALS, there is an up to 50% chance that each child will inherit the gene and develop the disease.

Amyotrophic Lateral Sclerosis Market Key Facts

  • The prevalent population of Amyotrophic lateral sclerosis (ALS) in the seven major markets was 71,628 in 2020, which is expected to increase by 2032.

  • The diagnosed prevalent cases of Amyotrophic Lateral Sclerosis in the United States were 18,824 in 2020.

  • In 2020, the patients with the limb site of onset accounted for 2,502 cases, followed by 1,251 cases with the bulbar site of onset, 801 cases with a cervical site of onset, and 450 cases with other uncertain regions in Germany. 

Amyotrophic Lateral Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Amyotrophic Lateral Sclerosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Amyotrophic Lateral Sclerosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Amyotrophic Lateral Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Amyotrophic Lateral Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to get launched during the study period. The analysis covers Amyotrophic Lateral Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Amyotrophic Lateral Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Latest Clinical and Commercial Developments in the Amyotrophic Lateral Sclerosis Therapeutics Market 

On September 29, 2022, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that the U.S. Food and Drug Administration (FDA) had approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol) for the treatment of adults with ALS.

On September 21, 2022, Cellenkos, Inc. announced that the US FDA had cleared its Investigational New Drug (IND) application for its therapy, CK0803, to initiate a Phase 1 safety study in patients with ALS.

Learn How Amyotrophic Lateral Sclerosis Market Will Evolve by 2032 @

Amyotrophic Lateral Sclerosis Therapeutics Analysis

The Amyotrophic lateral sclerosis (ALS) market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also the expected launch of emerging therapies during the forecasted period.

Some of the key companies in the Amyotrophic lateral sclerosis (ALS) Therapeutics Market include:

  • Cytokinetics

  • Orphazyme

  • Orion Pharma

  • Brainstorm Cell Therapeutics

  • Biogen

  • AB Science

  • Ionis Pharmaceuticals

  • Clene Nanomedicine

  • Neurosense therapeutics

  • Amylyx

  • MediciNova

  • Biohaven Pharmaceuticals

  • Prilenia Therapeutics

And many others.

Amyotrophic lateral sclerosis (ALS) therapies covered in the report include:

  • ODM-109

  • Arimoclomol

  • Reldesemtiv

  • Verdiperstat

  • NurOwn

  • IC14

  • BIIB067

  • CNM-Au8

And many more.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Amyotrophic Lateral Sclerosis Competitive Intelligence Analysis

4. Amyotrophic Lateral Sclerosis Market Overview at a Glance

5. Amyotrophic Lateral Sclerosis Disease Background and Overview

6. Amyotrophic Lateral Sclerosis Patient Journey

7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population (In US, EU5, and Japan)

8. Amyotrophic Lateral Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Amyotrophic Lateral Sclerosis Unmet Needs

10. Key Endpoints of Amyotrophic Lateral Sclerosis Treatment

11. Amyotrophic Lateral Sclerosis Marketed Products

12. Amyotrophic Lateral Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Amyotrophic Lateral Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Amyotrophic Lateral Sclerosis Market Outlook (In US, EU5, and Japan)

16. Amyotrophic Lateral Sclerosis Access and Reimbursement Overview

17. KOL Views on the Amyotrophic Lateral Sclerosis Market

18. Amyotrophic Lateral Sclerosis Market Drivers

19. Amyotrophic Lateral Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Intracranial Arterial Diseases Market

“Intracranial Arterial Diseases Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Intracranial Arterial Diseases Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States